197 related articles for article (PubMed ID: 35019268)
1. Bioresponsive Polyphenol-Based Nanoparticles as Thrombolytic Drug Carriers.
Yu H; Palazzolo JS; Zhou J; Hu Y; Niego B; Pan S; Ju Y; Wang TY; Lin Z; Hagemeyer CE; Caruso F
ACS Appl Mater Interfaces; 2022 Jan; 14(3):3740-3751. PubMed ID: 35019268
[TBL] [Abstract][Full Text] [Related]
2. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
Chen HA; Ma YH; Hsu TY; Chen JP
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
[TBL] [Abstract][Full Text] [Related]
3. Polyphenol-Functionalized Cubosomes as Thrombolytic Drug Carriers.
Yu H; Palazzolo JS; Ju Y; Niego B; Pan S; Hagemeyer CE; Caruso F
Adv Healthc Mater; 2022 Nov; 11(21):e2201151. PubMed ID: 36037807
[TBL] [Abstract][Full Text] [Related]
4. Novel and emerging therapies: thrombus-targeted fibrinolysis.
Lippi G; Mattiuzzi C; Favaloro EJ
Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
[TBL] [Abstract][Full Text] [Related]
5. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
6. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
[TBL] [Abstract][Full Text] [Related]
7. Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models.
Xu J; Zhang Y; Xu J; Liu G; Di C; Zhao X; Li X; Li Y; Pang N; Yang C; Li Y; Li B; Lu Z; Wang M; Dai K; Yan R; Li S; Nie G
Adv Mater; 2020 Jan; 32(4):e1905145. PubMed ID: 31788896
[TBL] [Abstract][Full Text] [Related]
8. Thrombus-specific theranostic nanocomposite for codelivery of thrombolytic drug, algae-derived anticoagulant and NIR fluorescent contrast agent.
Chang LH; Chuang EY; Cheng TM; Lin C; Shih CM; Wu AT; Jheng PR; Lu HY; Shih CC; Mi FL
Acta Biomater; 2021 Oct; 134():686-701. PubMed ID: 34358695
[TBL] [Abstract][Full Text] [Related]
9. Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy.
Absar S; Nahar K; Kwon YM; Ahsan F
Pharm Res; 2013 Jun; 30(6):1663-76. PubMed ID: 23468049
[TBL] [Abstract][Full Text] [Related]
10. Bacteria-propelled microtubular motors for efficient penetration and targeting delivery of thrombolytic agents.
Xie S; Mo C; Cao W; Xie S; Li S; Zhang Z; Li X
Acta Biomater; 2022 Apr; 142():49-59. PubMed ID: 35158079
[TBL] [Abstract][Full Text] [Related]
11. Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies.
Pitek AS; Wang Y; Gulati S; Gao H; Stewart PL; Simon DI; Steinmetz NF
Mol Pharm; 2017 Nov; 14(11):3815-3823. PubMed ID: 28881141
[TBL] [Abstract][Full Text] [Related]
12. Novel Thrombolytic Drug Based on Thrombin Cleavable Microplasminogen Coupled to a Single-Chain Antibody Specific for Activated GPIIb/IIIa.
Bonnard T; Tennant Z; Niego B; Kanojia R; Alt K; Jagdale S; Law LS; Rigby S; Medcalf RL; Peter K; Hagemeyer CE
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28159824
[TBL] [Abstract][Full Text] [Related]
13. Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke.
Ma H; Jiang Z; Xu J; Liu J; Guo ZN
Drug Deliv; 2021 Dec; 28(1):357-371. PubMed ID: 33517820
[TBL] [Abstract][Full Text] [Related]
14. Erythrocyte-Derived Nanoparticles as a Theranostic Agent for Near-Infrared Fluorescence Imaging and Thrombolysis of Blood Clots.
Vankayala R; Corber SR; Mac JT; Rao MP; Shafie M; Anvari B
Macromol Biosci; 2018 Apr; 18(4):e1700379. PubMed ID: 29479820
[TBL] [Abstract][Full Text] [Related]
15. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis.
Marsh JN; Senpan A; Hu G; Scott MJ; Gaffney PJ; Wickline SA; Lanza GM
Nanomedicine (Lond); 2007 Aug; 2(4):533-43. PubMed ID: 17716136
[TBL] [Abstract][Full Text] [Related]
16. In vivo thrombolysis with targeted microbubbles loading tissue plasminogen activator in a rabbit femoral artery thrombus model.
Hua X; Zhou L; Liu P; He Y; Tan K; Chen Q; Gao Y; Gao Y
J Thromb Thrombolysis; 2014 Jul; 38(1):57-64. PubMed ID: 24671732
[TBL] [Abstract][Full Text] [Related]
17. The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy.
Boulaftali Y; Lamrani L; Rouzaud MC; Loyau S; Jandrot-Perrus M; Bouton MC; Ho-Tin-Noé B
Thromb Haemost; 2012 May; 107(5):962-71. PubMed ID: 22552380
[TBL] [Abstract][Full Text] [Related]
18. Thrombolytic agents in development.
Verstraete M; Lijnen HR; Collen D
Drugs; 1995 Jul; 50(1):29-42. PubMed ID: 7588087
[TBL] [Abstract][Full Text] [Related]
19. Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke.
Xu J; Wang X; Yin H; Cao X; Hu Q; Lv W; Xu Q; Gu Z; Xin H
ACS Nano; 2019 Aug; 13(8):8577-8588. PubMed ID: 31339295
[TBL] [Abstract][Full Text] [Related]
20. Human hair derived uPA loaded capsules with dual near-infrared (I and II biowindows) laser responsive capabilities for multi-effective thrombolysis therapy.
Fang C; Zhong Z; Zhang T; Jia S; Ding X; Zhou W; Wang X
J Mater Chem B; 2020 Dec; 8(47):10854-10866. PubMed ID: 33185225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
